Boehringer Ingelheim Earns Breakthrough Therapy Designation for Pustular Psoriasis Drug

Title: Boehringer Ingelheim Granted Breakthrough Therapy Designation for Promising Pustular Psoriasis Treatment


Psoriasis is a chronic skin condition that affects millions of people worldwide, with various subtypes, including pustular psoriasis. While various treatments are available for psoriasis, progress has been made in search of specific treatments for various subtypes with better efficacy and patient outcomes. Recently, Boehringer Ingelheim, a global pharmaceutical company, has been granted Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for a promising new drug to treat pustular psoriasis. This blog will discuss the significance of this designation and highlight the potential implications of this new drug for pustular psoriasis treatment.

The Breakthrough Therapy Designation:

The FDA’s Breakthrough Therapy Designation signifies that the potential drug shows substantial improvement over existing treatments in treating a serious or life-threatening disease. Boehringer Ingelheim’s new drug, BI 655130, is an active human interleukin-36 receptor antibody that selectively and potently inhibits key disease-pathway consequences in pustular psoriasis. The promising results of Phase II clinical trials, including remission rates, safety profile and satisfying response durability, led to the award of Breakthrough Therapy Designation.

Pustular Psoriasis:

Pustular psoriasis is a rare and severe form of psoriasis where intensive and painful pustules and erythema appear suddenly, leading to systemic symptoms like fever, chills, and joint pain. The treatments available for this subtype are few, and patients need new, safe, and effective therapies. Boehringer Ingelheim’s new drug, BI 655130, precisely targets the IL-36 system, which is responsible for the symptoms of pustular psoriasis.

Potential Implications:

The Breakthrough Therapy Designation for BI 655130 holds enormous promise for patients suffering from pustular psoriasis. This designation brings hope for a new treatment option that is safe, efficient, and fast-acting. Furthermore, it offers encouragement for further research into targeted treatment options that tackle the complexities of psoriasis subtypes, leading to more customized and efficacious treatment options for patients. In terms of the development of targeted treatment approaches, Boehringer Ingelheim’s work is a significant breakthrough that could result in improved treatment protocols for a range of autoimmune diseases.

Advancing Research and Development:

Breakthrough Therapy Designation from the FDA is a significant milestone for Boehringer Ingelheim’s innovative drug. The designation provides the company with expedited development timelines, increased financial investment, and enhanced collaboration with regulatory authorities. The support and engagement of various stakeholders are crucial, including patients, healthcare providers, regulators, and researchers, to continue the advancement of research and development in this field.


The Breakthrough Therapy Designation for BI 655130‘s effective treatment for pustular psoriasis is a remarkable achievement in the field of dermatology. The promising clinical trial results of BI 655130 indicate superior safety, efficacy, and tolerability compared to current standards of care. The impact of this novel treatment option has vast implications for clinicians, researchers, patients, and regulatory authorities for not only pustular psoriasis but in other areas of rare autoimmune diseases. As this area of research and treatment strategy develops, we must continue to prioritize the development of targeted approaches to combat various autoimmune diseases, deliver sustainable medication options to patients, and offer them the best possible outcomes.